Is a possible benefit from longer-term docetaxel-based chemotherapy real?

A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Custirsen shows no benefit in combination with cabazitaxel in mCRPC

Early this morning, OncoGenex announced the result of final analysis of data from the Phase III AFFINITY trial of custirsen + cabazitaxel + prednisone in men with metastatic, castration-resistant prostate cancer (mCRPC) who had progressed after docetaxel chemotherapy. … READ MORE …

Planning out personalized therapy for metastatic prostate cancer

A new paper from researchers at the University of Santa Cruz and UCLA, just published in the journal Cell, has laid out the beginnings of a method to identify personalizable forms of therapy for men with metastatic forms of prostate cancer. … READ MORE …

Prevalence of DNA-repair germline mutations in men with metastatic prostate cancer

A new study in this week’s New England Journal of Medicine reports that DNA-repair germline mutations were found in nearly 12 percent of patients who had metastatic prostate cancer. … READ MORE …

A rise in the incidence of metastatic prostate cancer from 2004 to 2013

A newly published article in the journal Prostate Cancer and Prostatic Diseases suggests that there has been a relative 72 percent rise in the incidence of metastatic prostate cancer from 2004 to 2013 — mostly among men of 55 to 69 years of age. … READ MORE …

Results we already knew about for cabozantinib in mCRPC

Back in September 2014, Exelixis had announced (and we had reported) the failure of the COMET-1 trial to show a meaningful survival benefit for treatment with cabozantinib in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Personalized medicine is coming to life in management of advanced prostate cancer

A new study reported today in the New England Journal of Medicine is suggesting that every man with metastatic prostate cancer (regardless of his age or family history) should be tested for certain particular inherited mutations. … READ MORE …